Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
62(19):8784-8795
Retraction notice: Odanacatib for the treatment of postmenopausal osteoporosis
InChiKey: NOJNFULGOQGBKB-UHFFFAOYSA-M
GSK429286A has 61% oral bioavailability in male Sprague-Dawley rats
inhibition of PGD2 is inversely correlated with the plasma concentration of HPGDS inhibitor 1 in a time- and dose-dependent manner
SGX-523 - CAS# 1022150-57-7 Size:Solid 10 mg 62(19):8784-8795SGX523 is a novel, ATP competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol L and is >1,000 fold selective versus the >200 fold selectivity of other protein kinases tested in biochemical assays. Crystallographic study revealed that SGX523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for the
US$ 406.50
US$ 246.50
US$ 122.60
US$ 136.40
US$ 171.60
US$ 245.70
US$ 514.10
US$ 536.72
US$ 25.00
US$ 45.00
US$ 458.40
US$ 182.60
US$ 189.20